Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 245

1.

Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.

Setyawan J, Hodgkins P, Guérin A, Gauthier G, Cloutier M, Wu E, Erder MH.

J Med Econ. 2013 Oct;16(10):1203-15. doi: 10.3111/13696998.2013.832258. Epub 2013 Aug 23.

PMID:
23937642
2.

Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.

Setyawan J, Guérin A, Hodgkins P, Gauthier G, Cloutier M, Wu E, Erder MH.

J Med Econ. 2013 Nov;16(11):1275-89. doi: 10.3111/13696998.2013.839947. Epub 2013 Sep 19.

PMID:
24004347
3.

Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis.

Setyawan J, Hodgkins P, Guérin A, Gauthier G, Cloutier M, Wu EQ, Erder MH.

J Med Econ. 2013 Jul;16(7):962-75. doi: 10.3111/13696998.2013.800524. Epub 2013 Jun 7.

PMID:
23621503
4.

Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.

Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ.

J Med Econ. 2012;15(6):1078-87. doi: 10.3111/13696998.2012.689270. Epub 2012 Jun 14.

PMID:
22537226
5.

Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial.

Coghill DR, Banaschewski T, Lecendreux M, Zuddas A, Dittmann RW, Otero IH, Civil R, Bloomfield R, Squires LA.

Eur Child Adolesc Psychiatry. 2014 Feb;23(2):61-8. doi: 10.1007/s00787-013-0421-y. Epub 2013 May 25.

6.

A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.

Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Bloomfield R, Squires LA, Coghill DR.

CNS Drugs. 2013 Sep;27(9):743-51. doi: 10.1007/s40263-013-0086-6.

7.

Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.

Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

J Manag Care Pharm. 2007 Sep;13(7):561-9.

8.

Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.

Hodgkins P, Sasané R, Christensen L, Harley C, Liu F.

Curr Med Res Opin. 2011;27 Suppl 2:53-62. doi: 10.1185/03007995.2011.623158.

PMID:
21973231
10.

Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.

Christensen L, Sasané R, Hodgkins P, Harley C, Tetali S.

Curr Med Res Opin. 2010 Apr;26(4):977-89. doi: 10.1185/03007991003673617.

PMID:
20178404
11.

European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.

Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L.

Eur Neuropsychopharmacol. 2013 Oct;23(10):1208-18. doi: 10.1016/j.euroneuro.2012.11.012. Epub 2013 Jan 15.

12.

Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.

Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ.

J Manag Care Pharm. 2012 Nov-Dec;18(9):676-89.

14.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Findling RL.

Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Review.

PMID:
18555941
15.

Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder.

Olfson M, Marcus SC, Zhang HF, Wan GJ.

J Manag Care Pharm. 2007 Sep;13(7):570-7.

16.

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.

May DE, Kratochvil CJ.

Drugs. 2010;70(1):15-40. doi: 10.2165/11530540-000000000-00000.

PMID:
20030423
17.

Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder.

Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, Adeyi B, Squires LA, Coghill D.

CNS Drugs. 2013 Oct;27(10):829-40. doi: 10.1007/s40263-013-0095-5.

18.

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD.

Pediatrics. 2001 Jun;107(6):E105.

PMID:
11389303
19.

Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.

Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.

Curr Med Res Opin. 2014 Aug;30(8):1673-85. doi: 10.1185/03007995.2014.904772. Epub 2014 Apr 15. Review.

PMID:
24627974
20.

A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.

Katzman MA, Sternat T.

CNS Drugs. 2014 Nov;28(11):1005-33. doi: 10.1007/s40263-014-0175-1. Review.

PMID:
25120227
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk